Latest news with #ALK
Yahoo
2 days ago
- Business
- Yahoo
ALK participates at Jefferies Global Healthcare Conference 2025 in New York
ALK (ALKB:DC / OMX: ALK B) today announced that the company is participating at the Jefferies Global Healthcare Conference 2025 in New York City taking place from 3 - 5 June 2025. Claus Steensen Sølje, Executive Vice President and CFO, this morning (EDT) participated in a fireside chat at the conference. A webcast replay of the fireside chat is available on ALK's investor site: Investors | ALK or through this link. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy ('AIT') treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at Attachment InvestorNews_04June25_ALK Jefferies Global Healthcare ConferenceError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Here's Why Investors Should Avoid Alaska Air Group Stock for Now
Alaska Air Group ALK is facing significant challenges from rising operating expenses and a deteriorating liquidity position, which are adversely affecting the company's bottom line and making it an unattractive choice for investors' portfolios. Let's delve deeper. Southward Earnings Estimate Revision: The Zacks Consensus Estimate for current-quarter earnings has moved 46.6% south in the past 60 days. For the next year, the consensus mark for earnings has been revised 38.8% downward in the same time frame. The unfavorable estimate revisions indicate brokers' lack of confidence in the stock. Image Source: Zacks Investment Research Unimpressive Price Performance: Alaska shares have declined 21.4% year to date compared with the industry's 0.4% fall. Image Source: Zacks Investment Research Weak Zacks Rank: ALK currently carries a Zacks Rank #5 (Strong Sell). Bearish Industry Rank: The industry to which ALK belongs currently has a Zacks Industry Rank of 138 (out of 246). Such an unfavorable rank places it in the bottom 44% of Zacks show that 50% of a stock price movement is directly related to the performance of the industry group it belongs to. A mediocre stock within a strong group is likely to outclass a robust stock in a weak industry. Reckoning the industry's performance becomes imperative. Headwinds: Alaska Air Group is under increasing pressure on its bottom line due to rising expenses, which are challenging its financial stability. In the first quarter of 2025, the company's operating expenses continue to remain at an elevated level. The total operating expenses increased 39% year over year. This rise was largely driven by higher labor costs and elevated maintenance expenses. Labor costs, comprising salaries and benefits, accounted for 33.8% and rose 40% year over year. Maintenance expenses increased 80% on a year-over-year basis. The company is now grappling with the impact of these escalating costs, which are putting additional strain on its profitability and overall financial health. Moreover, a downward trend was observed in ALK's current ratio from 0.98 in 2021 to 0.61 in 2024. Further, in the first quarter of 2025, the current ratio was pegged at 0.58. This, indeed, is concerning as it questions the company's ability to meet its short-term obligations. Investors interested in the Transportation sector may also consider Copa Holdings CPA and Ryanair RYAAY. CPA currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CPA has an expected earnings growth rate of 14.3% for the current year. The company has an impressive earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 5.5%. Shares of CPA have risen 22.6% year to date. RYAAY currently sports a Zacks Rank of 1. RYAAY has an expected earnings growth rate of 30.5% for the current year. The company has a mixed earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, delivering an average beat of 46.6%. Shares of RYAAY have rallied 27.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ryanair Holdings PLC (RYAAY) : Free Stock Analysis Report Copa Holdings, S.A. (CPA) : Free Stock Analysis Report Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
23-05-2025
- Business
- Yahoo
Alaska Air Group (ALK) Gains As Market Dips: What You Should Know
Alaska Air Group (ALK) closed the latest trading day at $50.11, indicating a +0.68% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 0.04%. Coming into today, shares of the airline had gained 7.94% in the past month. In that same time, the Transportation sector gained 10.21%, while the S&P 500 gained 13.42%. Market participants will be closely following the financial results of Alaska Air Group in its upcoming release. The company's upcoming EPS is projected at $1.57, signifying a 38.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.66 billion, up 26.26% from the year-ago period. ALK's full-year Zacks Consensus Estimates are calling for earnings of $3.65 per share and revenue of $14.21 billion. These results would represent year-over-year changes of -25.05% and +21.09%, respectively. It's also important for investors to be aware of any recent modifications to analyst estimates for Alaska Air Group. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 29.65% lower. Alaska Air Group is currently sporting a Zacks Rank of #5 (Strong Sell). In terms of valuation, Alaska Air Group is presently being traded at a Forward P/E ratio of 13.63. This expresses a premium compared to the average Forward P/E of 8.92 of its industry. One should further note that ALK currently holds a PEG ratio of 0.51. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Transportation - Airline industry had an average PEG ratio of 0.94. The Transportation - Airline industry is part of the Transportation sector. This group has a Zacks Industry Rank of 89, putting it in the top 37% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
News18
19-05-2025
- Health
- News18
Coping With A Lung Cancer Diagnosis? What Every Indian Patient Needs to Know
Last Updated: Lung Cancer in now one of the leading causes of cancer-related deaths in the country A lung cancer diagnosis depicts one of those moments that divide life in two—Before, and, After. For many Indian patients, the information comes as a personal catastrophe, rather than simply a medical diagnosis. The impact of having your doctor telling you that you have lung cancer, when you were expecting your persistent cough to be asthma, or an allergy, is hard to process, mentally; and even harder to talk about. Far from being rare, anymore, Lung Cancer in now one of the leading causes of cancer-related deaths in the country. Alarmingly, a growing number of these patients are non-smokers. Air pollution, indoor smoke from cooking, genetic predispositions, and even occupational exposure to harmful substances are contributing to a spike, especially in urban areas, such as Delhi, Mumbai, and Bengaluru. Dr. Mallikarjun, Consultant, Interventional Pulmonology and Sleep Medicine, HCG Cancer Hospital, KR Road Bengaluru shares all you need to know: When you come face-to-face with a devastating truth, the thing to do is to pause and take a breath—literally. Gather your mental and emotional reserves. Then begin asking the right questions: • What type of lung cancer is it? • What stage are we looking at? • What are the treatment options? • What kind of support—medical, emotional, financial—will I need? • Surgery, to remove localized tumours • Chemotherapy and radiation • Targeted therapy, for cancers with specific genetic mutations (such as EGFR or ALK) • Immunotherapy, which leverages the body's own immune system, to fight cancer Numerous tertiary centres in India now provide Advanced Cancer Care. The Overlooked Emotional Aftershock The diagnosis leaves many patients with a sense of grief, guilt, or even shame—particularly if they were smokers. Some withdraw. Others panic. Mental health support is vital, but in India, this reality is insufficiently recognized. Anxiety, depression, and sleep disturbances are common, but manageable. Counselling, online or in-person, mindfulness practices, including yoga, meditation, or even joining lung cancer support groups (like Lung Connect India) can curb emotional isolation. Nutrition and Gut Health: Fuelling the Body to Fight Nutrition is often neglected during treatment, but it can be a game-changer. Chemo or radiation can induce nausea, weight loss, fatigue, or gut discomfort. A balanced, high-protein, antioxidant-rich Indian diet (with dals, curd, fruits, nuts, and green vegetables) can help the body to cope and recover faster. Fermented foods such as buttermilk and idli can enhance gut health, and support treatment. Small, frequent meals, rather than forced, large ones help to manage low appetite. Consulting a clinical nutritionist specialized in oncology care is highly recommended. Side Effects Are Real—and So Is Support Side effects of treatment, such as hair loss, fatigue, changes in taste or skin tone must be recognized as equally physical and emotional. These, including the smallest discomforts can be effectively managed through open communication with your doctor. Medications and practices exist, to manage almost every symptom. No need to suffer in silence. The Cost Factor? Cancer care can be expensive, but many financial aid options exist. • Ayushman Bharat Yojana offers support to eligible families. • State government health schemes, particularly in Tamil Nadu, Kerala, and Andhra Pradesh. • Indian Cancer Society, and other NGOs, also offer cancer aid funding. Promptly consult the hospital's medical social worker, or your oncologist, about paperwork and applications. Faith, Family, and Finding New Meaning Many patients discover a renewed sense of purpose, after diagnosis. Spending more time with family, reconnecting with friends, or returning to a spiritual practice, all illustrate that coping and healing extend beyond medical support. In Indian households, extended family plays a big role, and that support can be both a comfort and a responsibility. Don't hesitate to set boundaries or ask for space, when needed. The Power of Shared Experience One of the most powerful ways to heal is to know you're not the only one. Online forums, WhatsApp groups for cancer patients, and hospital-organized meetups are growing in India. Listening to someone else's survival story can profoundly restore hope. Lung Cancer is not an End—It is a New Chapter The agony is real, but the internal powerhouse should persist. Recovering from lung cancer is not impossible—and may even be transformational, with optimal Medicare, emotional support and community bonding. tags : cnn-news18 latest news lifestyle Lung lung cancer types lung damage lung disease lung infection lung transplant news18 Smoking and Lung Cancer world lung cancer day Location : New Delhi, India, India First Published: May 19, 2025, 07:40 IST News lifestyle » health-and-fitness Coping With A Lung Cancer Diagnosis? What Every Indian Patient Needs to Know
Yahoo
15-05-2025
- Business
- Yahoo
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ...
Total Revenue: $8 million for Q1 2025. US Net Product Revenue for neffy: $7.8 million. Collaboration Revenue: $0.2 million from ALK agreement. Cost of Goods Sold: $1.1 million for Q1 2025. R&D Expenses: $3 million for Q1 2025. SG&A Expenses: $41.1 million for Q1 2025. Planned DTC Campaign Investment: $40 million to $50 million for the remainder of 2025. Projected 2025 Operating Expenses: $210 million to $220 million, excluding stock-based compensation and COGS. Net Loss: $33.9 million, or $0.35 per share, for Q1 2025. Cash, Cash Equivalents, and Short-term Investments: $275.7 million as of March 31, 2025. Warning! GuruFocus has detected 4 Warning Signs with SPRY. Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ARS Pharmaceuticals Inc (NASDAQ:SPRY) successfully launched neffy, the first needle-free epinephrine treatment, with $7.8 million in US net product revenue in Q1 2025. The company expanded commercial insurance coverage for neffy from 27% to 57%, with ongoing payer discussions to further increase coverage. Neffy 1-milligram dose was approved by the FDA for children, representing a significant portion of the pediatric market. A strategic collaboration with ALK-Abello expanded ARS Pharmaceuticals Inc (NASDAQ:SPRY)'s promotional network to over 20,000 healthcare providers, including 9,000 pediatricians. The company is launching a comprehensive direct-to-consumer campaign to increase patient awareness and drive prescription growth for neffy. ARS Pharmaceuticals Inc (NASDAQ:SPRY) reported a net loss of $33.9 million for Q1 2025, indicating financial challenges despite revenue growth. The cost of goods sold is expected to increase as the company uses up its zero-cost inventory. Prior authorization requirements remain a barrier for some patients, with only 57% of commercial lives having access to neffy without prior authorization. The company anticipates significant operating expenses of $210 million to $220 million for 2025, driven by marketing and commercialization efforts. Market share for neffy is currently low at 1.3% overall, though higher among targeted high-prescribing physicians. Q: How much of the first-quarter sales figure is attributed to inventory, and what are your expectations for inventory contribution over the next two quarters? A: Richard Lowenthal, President and CEO, stated that the first-quarter numbers were minimally influenced by inventory. The sales were primarily from 2-milligram doses, and inventory levels are steady. They do not expect inventory to significantly impact sales in the upcoming quarters. Q: What is the current gross-to-net discount, and how has it changed from the fourth quarter to the first quarter? A: Kathleen Scott, CFO, explained that the gross-to-net discount was higher in Q4 than in Q1. With increasing insurance coverage, the gross-to-net is expected to decrease to around 50% as the year progresses. Q: What do you expect the cost of goods sold (COGS) to be once the current inventory is used up? A: Kathleen Scott noted that some inventory was expensed prior to FDA approval, which currently benefits COGS. As this inventory is used, COGS will increase slightly, but the zero-cost inventory primarily involves raw materials, with manufacturing costs still being incurred. Q: Can you discuss the impact of the neffy Experience Program on physician adoption and any feedback received? A: Richard Lowenthal highlighted that the neffy Experience Program has been successful, with over 2,500 physicians enrolled. Feedback has been positive, with results similar to injections, where about 90% of patients respond to a single dose. Plans are in place to expand the program and potentially publish the results. Q: How are you tracking against your goal of 80% commercial insurance coverage by the third quarter? A: Richard Lowenthal mentioned ongoing negotiations with major insurers like Caremark and Aetna. Currently, 57% of patients have coverage without prior authorization, and efforts are underway to increase this percentage to meet the 80% goal. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
